STTR Phase I: Aptamer Biosensors with the Longevity and Technology Compatibility Required for Continuous Biosensing Devices Beyond Glucose

这个小型企业技术转移(STTR)第一阶段项目的更广泛的影响/商业潜力是改善有可穿戴生物传感器需求的患者的临床结果。该项目将开发可穿戴的连续葡萄糖生物传感器平台，以满足广泛的疾病和健康应用，例如测量与糖尿病管理相关的额外分子，改善心血管疾病的管理，以及定制剂量的治疗药物监测。除了在美国影响人类健康(特别是慢性病)外，商业市场也很重要，每年价值约1200亿美元。此外，这些生物传感器将直接向患者提供数据，为他们的决定提供信息。这个小型企业技术转让(STTR)第一阶段项目将解决阻碍连续诊断监测平台增加临床实用功能的限制，而不仅仅是用酶传感器检测血糖。与酶葡萄糖传感器不同的是，电化学适配子传感器具有很高的特异性和灵敏度，能够快速适应于体内其他分子的检测。然而，目前适体传感器在活体动物中迅速降解(6-12小时)，必须通过高度侵入性的切口插入。这一STTR第一阶段项目将展示适体生物传感器在真实生物流体环境中的强大和更持久的功能。它将使用一种软件启用的方法，其中只插入一个电极，使得到的设备真正具有最小的侵入性。该奖项反映了NSF的法定使命，并通过使用基金会的智力优势和更广泛的影响审查标准进行评估，被认为值得支持。

The broader impact/commercial potential of this Small Business Technology Transfer (STTR) Phase I project is to improve clinical outcomes for patients with wearable biosensor needs. This project will develop wearable continuous glucose biosensor platforms to address a broad set of disease and wellness applications, such as measuring additional molecules relevant to diabetes management, improving management of cardiovascular diseases, and therapeutic drug monitoring to customize dosages. In addition to impacting human health (particularly for chronic diseases) in the United States, the commercial market is significant and valued at approximately $120 B/year. Furthermore, these biosensors will provide data directly to patients to inform their decisions. This Small Business Technology Transfer (STTR) Phase I project will address the limitations which have prevented continuous diagnostic monitoring platforms from adding clinical utility beyond sensing glucose with enzymatic sensors. Unlike enzymatic glucose sensors, electrochemical aptamer sensors are rapidly adaptable to measuring other molecules in the body with high specificity and sensitivity. However, aptamer sensors currently degrade rapidly in live animals (6-12 hours) and must be inserted through a highly-invasive incision. This STTR Phase I project will demonstrate robust and longer-lasting functioning of aptamer biosensors in a real biofluid environment. It will use a software-enabled method in which only one electrode is inserted, making the resulting device truly minimally invasive.This award reflects NSF's statutory mission and has been deemed worthy of support through evaluation using the Foundation's intellectual merit and broader impacts review criteria.